🟢 Opus Genetics is trading 7.18% up in pre-market after renewed Phase 3 focus

Opus Genetics is trading at $3.96, up 7.18%, after renewed investor focus on completing enrollment in the registrational Phase 3 OPGx-LCA5 trial.

• The company announced the milestone on August 3, 2026; dosing is expected in the fourth quarter, with topline data anticipated by the end of 2027.
• Major U.S. indices were broadly flat in pre-market trading, and no new August 19 announcement or reliable pre-market volume figure was identified.